AVArun Venkiteswaran

Arun Venkiteswaran

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Arun Venkiteswaran has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Assessing Atopic Dermatitis severity in children from Georgia: the correlation of inflammatory blood markers to the Eczema Area and Severity Index

    by Janadi Karawita, Faiza Yasmine Kabachi, Aliya Modak, Arun Venkiteswaran, Rawiah Haseeb, Nikoloz Papiashvili, Kevin Jacob, Veriko Abralava

    Atopic dermatitis (AD) is a chronic inflammatory skin condition prevalent among children worldwide. Systemic inflammation is a key factor in its pathophysiology. Correlating blood markers with Eczema Area and Severity Index (EASI) can reveal information about the severity and activity of the disorder, allowing for more focused treatment. A retrospective analysis was conducted on 22 patients aged 3 months to 18 years. Blood parameters, such as Eosinophil Relative Count (ERC), Neutrophil/Lymphocyte Ratio (NLR), Eosinophil/Lymphocyte Ratio (ELR), and Basophil/Lymphocyte Ratio (BLR), were correlated with the Eczema Area and Severity Index (EASI). A strong positive correlation was observed between EASI scores and ERC (r = 0.69, p < 0.001) and with ELR (r = 0.71, p < 0.001). No statistical significance was seen between EASI scores and the NLR (r = 0.2059, p = 0.3578) and BLR (r = 0.1026, p = 0.6494). No significant association was found between age and EASI scores (r = -0.0351, p = 0.8767). ERC and ELR have the potential to serve as objective blood markers for assessing AD severity. However, more research in pediatric populations with a larger sample size is needed to establish a conclusive association for clinical practice.

  • A systematic review of the efficacy and safety of anti-amyloid beta monoclonal antibodies in treatment of Alzheimer’s disease

    by Akanksha Chhabra, Siddhant Solanki, Prithvi Saravanabawan, Arun Venkiteswaran, NagaTarang Nimmathota, Nishi Manojkumar Modi

    Alzheimer's disease can cause dementia through brain matter degradation. This study investigates the monoclonal antibody usage for AD treatment, following PRISMA 2020 guidelines, and aims to discern the monoclonal antibody that offers the optimal balance of efficacy and safety for individuals with AD. A systematic search was conducted across databases such as PubMed, Cochrane Library, and clinical trial registries for randomized controlled trials. The quality of studies was assessed using the Cochrane risk of bias 2 tool. Cognitive function and daily activities were evaluated using MMSE, ADAS-Cog, and CDR-SB test data. According to CDR-SB measurements, lecanemab showed effectiveness in reducing brain amyloid and cognitive decline, with a change from baseline of 1.21. Aducanumab resulted in a decrease of -0.39 (-22%). Bapineuzumab showed no significant benefit, with scores of 2.4 (2.8). Gantenerumab, scoring 1.69 (1.37, 2.01), reduces amyloid, particularly in early Alzheimer's stages. Crenezumab was ineffective, with a score of 3.61. The findings provide various perspectives. Lecanemab showed the most promise in brain amyloid reduction and decelerating cognitive decline compared to the other therapies. Further research is needed, highlighting the necessity of AD therapeutic research to alter AD's trajectory and provide reliable treatment. www.crd.york.ac.uk/prospero identifier is CRD42024504358.